Accordingly, CHRNA7 expression and the CAP activation increase would contribute to the reduction of systemic inflammation in this population and could become a new therapeutic target in the treatment of obesity and T2DM. The gene discussed is CHRNA7; the disease is type 2 diabetes mellitus.